000			02025 a2200613 4500
005			20250516131317.0
264		0	_c20140204
008			201402s 0 0 eng d
022			_a1476-5365
024	7		_a10.1038/bmt.2012.261 _2doi
040			_aNLM _beng _cNLM
100	1		_aMedd, P G
245	0	0	_aEvidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. _h[electronic resource]
260			_bBone marrow transplantation _cJul 2013
300			_a982-7 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAcute Disease
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAlemtuzumab
650	0	4	_aAllografts
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aGraft vs Host Disease _xetiology
650	0	4	_aGraft vs Leukemia Effect
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xmortality
650	0	4	_aSex Factors
650	0	4	_aSocieties, Medical
650	0	4	_aStem Cell Transplantation
650	0	4	_aSurvival Rate
650	0	4	_aTransplantation Conditioning
650	0	4	_aUnited Kingdom
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aPeniket, A J
700	1		_aLittlewood, T J
700	1		_aPearce, R
700	1		_aPerry, J
700	1		_aKirkland, K E
700	1		_aShaw, B E
700	1		_aPotter, M N
700	1		_aCraddock, C F
700	1		_aMilligan, D W
700	1		_aFielding, A K
700	1		_aMarks, D I
700	1		_aCook, G
773	0		_tBone marrow transplantation _gvol. 48 _gno. 7 _gp. 982-7
856	4	0	_uhttps://doi.org/10.1038/bmt.2012.261 _zAvailable from publisher's website
999			_c22418420 _d22418420